Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to IPSS) With Excess of Marrow Blasts

NCT00565656 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Nice as lead sponsor.

NCT NCT00565656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00565656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to IPSS) With Excess of Marrow Blasts
Lead sponsor
Centre Hospitalier Universitaire de Nice
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2007
Completion date
July 31, 2010
Enrollment
40 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes